INFI News and Press, Infinity Pharmaceuticals Inc. From 03/09/21

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, wil...

Key test results will be published during the course of the year. There appear to be sufficient funds to determine whether 2021 progress will provide a buoyant long-term future. Cooperation deals with big pharma will be crucial for long-term cash position. The company is targe...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9 th – Wednesday, March 10 th , 2021. The...

Trying to pick the stock that will win the year is a fun game to play. Not to mention, if you're smart in your selection, you can come away with massive returns. I came pretty close last year with my Novavax pick; the stock shot up 2,700% in 2020. Can I name the winner of 2021? It's unl...

Piper Sandler analyst Edward Tenthoff has initiated coverage of Infinity Pharmaceuticals (INFI) with an overweight rating and a $7 price target.The company's sole clinical candidate, eganelisib, is a first-in-class, oral, immuno-oncology candidate that selectively inhibits phosphoinositide-3-...

Analysts Are Bullish On These 4 Penny Stocks We’ve discussed penny stocks and analyst ratings many times before. Are these firms always correct about the companies they cover? No, but the information they offer doesn’t hurt when it comes to research. These firms will o...

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundament...

Infinity Pharmaceuticals (INFI) down 8% premarket after pricing its public offering of 21M common shares at $3.80/share.Expected gross proceeds are $79.8M.Underwriters' over-allotment is an additional 3.15M shares. Net proceeds will be used for the development of eganelisib, for gen...

Infinity Pharmaceuticals, Inc . (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamen...

Infinity Pharmaceuticals (INFI) traded 4% down after hours post commencing an underwritten public offering; underwriters granted 30-day option to purchase an additional 15% of the shares.Offer size, terms not yet disclosed.Proceeds to be used for the continued clinical dev...